# Evaluate the Efficacy and Safety of D-2570 in Subjects With Moderate to Severe Plaque Psoriasis

> **NCT07130604** · PHASE3 · RECRUITING · sponsor: **InventisBio Co., Ltd** · enrollment: 390 (estimated)

## Conditions studied

- Plaque Psoriasis

## Interventions

- **DRUG:** D-2570
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07130604
- **Lead sponsor:** InventisBio Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-18
- **Primary completion:** 2027-07-28
- **Final completion:** 2027-07-28
- **Target enrollment:** 390 (ESTIMATED)
- **Last updated:** 2025-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07130604

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07130604, "Evaluate the Efficacy and Safety of D-2570 in Subjects With Moderate to Severe Plaque Psoriasis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07130604. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*